Imedex® is an industry leader in providing certified, independent continuing medical education to health care professionals.

May 5-7, 2016
Zagreb, Croatia

MPN Therapies: Emerging Concepts for Enhanced Outcomes

A Satellite Symposium during the European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes Congress

6 May 2016
Sherarton Zagreb
Zagreb, Croatia

Symposium Chair

Alessandro M. Vannucchi, MD
University of Florence
Hospital Careggi
Florence, Italy

Continuing Education

ACCMEImedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex®, LLC designates this live educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Who Should Attend
This live educational activity is designed to meet the educational needs of European hematologists, medical oncologists, and other healthcare professionals (physicians, physicians-in-training, oncology nurses, pharmacists, physician assistants, etc.) who are involved and/or interested in the treatment of patients with myeloproliferative neoplasms (MPN).

Objectives
Upon successful completion of this educational activity, participants should be able to:

  • Enhance clinical outcomes and quality of life measures in patients with MPN, healthcare professionals require expert analysis of optimal management strategies and guidance to effectively incorporate novel regimens into everyday clinical practice.
  • Assess data from ongoing and finalized clinical trials utilizing JAK2 inhibitors as monotherapy or in combination with other therapies for the optimal management of patients with MPN
  • Evaluate strategies for enhancing quality of life measures in patients with MPN
  • Formulate optimal evidence-based strategies for the management of patients with MPN, taking into consideration disease stage, patient cytogenetics, and timing for initiation of therapy

Faculty

Mario Cazzola, MD
University of Pavia
Pavia, Italy

Francisco Cervantes, MD, PhD
Hospital Clínic
Bareclona, Spain

Paola Guglielmelli, MD, PhD
University of Florence
Florence, Italy

Alessandro M. Vannucchi, MD
University of Florence Medical School
Florence, Italy

Agenda

12:30 pm

Welcome, opening remarks, and pre-activity learner survey
Alessandro M. Vannucchi, MD

12:35 pm

Lecture: Emerging JAK2 inhibitor combination treatment strategies in MF
Francisco Cervantes, MD, PhD

12:50 pm

Lecture: What is the real clinical benefit of JAK2 inhibitors in patients with MPN
Paola Guglielmelli, MD, PhD

13:05 pm

Debate: Should we treat early-stage MF?
No, only observation: Mario Cazzola, MD
Yes, initiate therapy: Alessandro M. Vannucchi, MD

13:35 pm

Panel discussion: Optimal management of patients with MPN to enhance clinical outcomes and quality of life
Presenter: Alessandro M. Vannucchi, MD
Presenter: Mario Cazzola, MD, Francisco Cervantes, MD, PhD, Paola Guglielmelli, MD, PhD

13:55 pm

Concluding remarks, recap of key points, and post-activity polling via ARS
Alessandro M. Vannucchi, MD

Support

The following company has provided an educational grant in support of this symposium::

Novartis Oncology

Registration

Registration is complimentary. Please remember to bring your Badge. Space is limited and available on a first come first serve basis.